Foresee Pharmaceuticals Management
Management criteria checks 2/4
Foresee Pharmaceuticals' CEO is Ben Chien, appointed in Mar 2021, has a tenure of 3.67 years. directly owns 0.68% of the company’s shares, worth NT$75.77M. The average tenure of the management team and the board of directors is 4.1 years and 8.7 years respectively.
Key information
Ben Chien
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3.7yrs |
| CEO ownership | 0.7% |
| Management average tenure | 4.1yrs |
| Board average tenure | 8.7yrs |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -NT$859m |
| Mar 31 2024 | n/a | n/a | -NT$977m |
| Dec 31 2023 | n/a | n/a | -NT$1b |
| Sep 30 2023 | n/a | n/a | -NT$906m |
| Jun 30 2023 | n/a | n/a | -NT$833m |
| Mar 31 2023 | n/a | n/a | -NT$530m |
| Dec 31 2022 | NT$16m | NT$12m | -NT$473m |
| Sep 30 2022 | n/a | n/a | -NT$458m |
| Jun 30 2022 | n/a | n/a | -NT$467m |
| Mar 31 2022 | n/a | n/a | -NT$532m |
| Dec 31 2021 | NT$12m | NT$10m | -NT$569m |
| Sep 30 2021 | n/a | n/a | -NT$429m |
| Jun 30 2021 | n/a | n/a | -NT$458m |
| Mar 31 2021 | n/a | n/a | -NT$560m |
| Dec 31 2020 | NT$8m | NT$8m | -NT$511m |
| Sep 30 2020 | n/a | n/a | -NT$546m |
| Jun 30 2020 | n/a | n/a | -NT$527m |
| Mar 31 2020 | n/a | n/a | -NT$556m |
| Dec 31 2019 | NT$12m | NT$7m | -NT$487m |
| Sep 30 2019 | n/a | n/a | -NT$568m |
| Jun 30 2019 | n/a | n/a | -NT$511m |
| Mar 31 2019 | n/a | n/a | -NT$489m |
| Dec 31 2018 | NT$9m | n/a | -NT$552m |
Compensation vs Market: Insufficient data to establish whether Ben's total compensation is reasonable compared to companies of similar size in the TW market.
Compensation vs Earnings: Ben's compensation has increased whilst the company is unprofitable.
CEO
Ben Chien
3.7yrs
Tenure
NT$16,166,000
Compensation
Dr. Benjamin Chien, also known as Ben, Ph.D. Founded Foresee Pharmaceuticals Co., Ltd. and serves as its Chairman. Dr. Chien served as President at Foresee Pharmaceuticals Co., Ltd.since March 25, 2021 un...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 3.7yrs | NT$16.17m | 0.68% NT$ 75.8m | |
| Co-founder & Chief Technology Officer | no data | NT$3.06m | 0.42% NT$ 47.2m | |
| Chief Business Officer & Chief Operating Officer | no data | NT$585.00k | no data | |
| Chief Scientific Officer | 9.2yrs | NT$4.99m | 0.085% NT$ 9.5m | |
| Chief Medical Officer & Director | no data | NT$1.99m | 0.56% NT$ 62.4m | |
| Senior Vice President of Pharmaceutics & Manufacturing | 3.9yrs | NT$5.46m | 0.058% NT$ 6.6m | |
| Chief Financial Officer | 5.1yrs | no data | 0.12% NT$ 13.9m | |
| Accounting Officer | less than a year | no data | no data | |
| Consultant | 4.3yrs | no data | no data | |
| Consultant | 6yrs | no data | no data | |
| Senior Vice President of Clinical Development | 1.6yrs | no data | 0.029% NT$ 3.3m |
4.1yrs
Average Tenure
Experienced Management: 6576's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 11.8yrs | NT$16.17m | 0.68% NT$ 75.8m | |
| Chief Medical Officer & Director | 11.8yrs | NT$1.99m | 0.56% NT$ 62.4m | |
| Director | 9.3yrs | NT$25.00k | 0.036% NT$ 4.0m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Representative Director | 11.8yrs | NT$35.00k | 0.063% NT$ 7.1m | |
| Independent Director | 8.7yrs | NT$440.00k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | 8.7yrs | NT$35.00k | 0.0095% NT$ 1.1m | |
| Independent Director | 6.4yrs | NT$440.00k | no data | |
| Independent Director | 8.7yrs | NT$440.00k | 0.082% NT$ 9.2m | |
| Independent Director | 1.4yrs | no data | no data |
8.7yrs
Average Tenure
Experienced Board: 6576's board of directors are considered experienced (8.7 years average tenure).